Lactobacillus brevis Alleviates DSS-Induced Colitis by Reprograming Intestinal Microbiota and Influencing Serum Metabolome in Murine Model

Abstract

The aim of this study was to examine the effects of <i>Lactobacillus brevis</i> on the microbial community and serum metabolome in colitis induced by dextran sulfate sodium (DSS). ICR mice were randomly distributed into three treatment groups: (i) <i>L. brevis</i> treatment alone (control), (ii) DSS administration alone, and (iii) treatment with <i>L. brevis</i> and DSS. Our results demonstrate that <i>L. brevis</i> treatment significantly alleviated DSS-induced body weight loss and colon inflammation. In addition, LC-MS analysis of serum metabolites revealed that <i>L. brevis</i> treatment increased the serum level of metabolites against inflammatory responses or oxidative stressors caused by DSS in the murine model. By detecting colonic microbiota, <i>L. brevis</i> increased colonic microbial diversity after challenging with DSS, and increased the relative abundance of Alloprevotella at genus, but Bacteroidales was reduced (<i>P</i> < 0.05). These result indicated that <i>L. brevis</i> could lower the severity of colitis induced by DSS via improving reprogramming the serum metabolome and intestinal microbiota. These findings suggest that the probiotic <i>L. brevis</i> may prevent tissue damage from colitis.